---
schema_version: "secwatch.filing_event.v1"
accession: "0001299130-25-000083"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2025-04-09T23:59:59+00:00"
generated_at: "2026-05-23T18:04:13.739756+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PacBio reports preliminary Q1 revenue $36.9M, down 5% YoY; cuts annual opex run rate by $45-50M

## Summary
- Preliminary Q1 2025 revenue $36.9M vs $38.8M YoY; instrument revenue fell to $10.8M from $19.0M.
- Record consumable revenue of $20.1M (up from $16.0M); shipped 28 Vega systems in Q1 (vs 0 prior).
- Announces plan to reduce annualized non-GAAP opex run rate by $45-50M; expects ~$5M severance costs in 2025.
- Reiterates FY2025 revenue guidance $155-170M and non-GAAP gross margin 35-40%; targets positive cash flow by end of 2027.
- Cash and investments $343.1M at Q1 end; expects higher ending balance after cost cuts.

## SEC filing metadata
- accession: 0001299130-25-000083
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2025-04-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000129913025000083/0001299130-25-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000129913025000083/pacb-20250409.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001299130-25-000083
- JSON: https://secwatch.observer/filing/0001299130-25-000083.json
- Plain text: https://secwatch.observer/filing/0001299130-25-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.